Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Edgar Turner Overton

Showing results (41-50 of 50) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 50 results.
Plos One|April 14, 2018
Immunogenicity and safety of three consecutive production lots of the non replicating smallpox vaccine MVA: A randomised, double blind, placebo controlled phase III trialEdgar Turner Overton, Steven J Lawrence, Eva Wagner, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 12, 2017
The Impact of Statin and Angiotensin-Converting Enzyme Inhibitor/Angiotensin Receptor Blocker Therapy on Cognitive Function in Adults With Human Immunodeficiency Virus InfectionKristine M Erlandson, Douglas Kitch, C William Wester, et al.
AIDS Research and Human Retroviruses|April 12, 2013
Relationships among HIV infection, metabolic risk factors, and left ventricular structure and functionWilliam Todd Cade, Edgar Turner Overton, Kristin Mondy, et al.
Open Forum Infectious Diseases|September 18, 2015
Safety and Immunogenicity of Modified Vaccinia Ankara-Bavarian Nordic Smallpox Vaccine in Vaccinia-Naive and Experienced Human Immunodeficiency Virus-Infected Individuals: An Open-Label, Controlled Clinical Phase II TrialEdgar Turner Overton, Jack Stapleton, Ian Frank, et al.
The Journal of Infectious Diseases|January 8, 2019
Rapid Boosting of HIV-1 Neutralizing Antibody Responses in Humans Following a Prolonged Immunologic Rest PeriodPaul Spearman, Georgia D Tomaras, David C Montefiori, et al.
American Heart Journal|April 1, 2019
Rationale and design of the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE)Steven K Grinspoon, Kathleen V Fitch, Edgar Turner Overton, et al.
AIDS (London, England)|July 25, 2022
Diet in a global cohort of adults with HIV at low-to-moderate traditional cardiovascular disease riskKathleen V Fitch, Sara A McCallum, Kristine M Erlandson, et al.
The New England Journal of Medicine|July 22, 2015
Daclatasvir plus Sofosbuvir for HCV in Patients Coinfected with HIV-1David L Wyles, Peter J Ruane, Mark S Sulkowski, et al.
Open Forum Infectious Diseases|October 22, 2024
Effects of Pitavastatin on COVID-19 Incidence and Seriousness Among a Global Cohort of People With HIVMarkella V Zanni, Triin Umbleja, Carl J Fichtenbaum, et al.
American Heart Journal|April 1, 2019
Rationale and design of the Mechanistic Substudy of the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE): Effects of pitavastatin on coronary artery disease and inflammatory biomarkersUdo Hoffmann, Michael T Lu, Devvora Olalere, et al.
Pageof 5

Showing results (41-50 of 50) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 50 results.
Plos One|April 14, 2018
Immunogenicity and safety of three consecutive production lots of the non replicating smallpox vaccine MVA: A randomised, double blind, placebo controlled phase III trialEdgar Turner Overton, Steven J Lawrence, Eva Wagner, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 12, 2017
The Impact of Statin and Angiotensin-Converting Enzyme Inhibitor/Angiotensin Receptor Blocker Therapy on Cognitive Function in Adults With Human Immunodeficiency Virus InfectionKristine M Erlandson, Douglas Kitch, C William Wester, et al.
AIDS Research and Human Retroviruses|April 12, 2013
Relationships among HIV infection, metabolic risk factors, and left ventricular structure and functionWilliam Todd Cade, Edgar Turner Overton, Kristin Mondy, et al.
Open Forum Infectious Diseases|September 18, 2015
Safety and Immunogenicity of Modified Vaccinia Ankara-Bavarian Nordic Smallpox Vaccine in Vaccinia-Naive and Experienced Human Immunodeficiency Virus-Infected Individuals: An Open-Label, Controlled Clinical Phase II TrialEdgar Turner Overton, Jack Stapleton, Ian Frank, et al.
The Journal of Infectious Diseases|January 8, 2019
Rapid Boosting of HIV-1 Neutralizing Antibody Responses in Humans Following a Prolonged Immunologic Rest PeriodPaul Spearman, Georgia D Tomaras, David C Montefiori, et al.
American Heart Journal|April 1, 2019
Rationale and design of the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE)Steven K Grinspoon, Kathleen V Fitch, Edgar Turner Overton, et al.
AIDS (London, England)|July 25, 2022
Diet in a global cohort of adults with HIV at low-to-moderate traditional cardiovascular disease riskKathleen V Fitch, Sara A McCallum, Kristine M Erlandson, et al.
The New England Journal of Medicine|July 22, 2015
Daclatasvir plus Sofosbuvir for HCV in Patients Coinfected with HIV-1David L Wyles, Peter J Ruane, Mark S Sulkowski, et al.
Open Forum Infectious Diseases|October 22, 2024
Effects of Pitavastatin on COVID-19 Incidence and Seriousness Among a Global Cohort of People With HIVMarkella V Zanni, Triin Umbleja, Carl J Fichtenbaum, et al.
American Heart Journal|April 1, 2019
Rationale and design of the Mechanistic Substudy of the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE): Effects of pitavastatin on coronary artery disease and inflammatory biomarkersUdo Hoffmann, Michael T Lu, Devvora Olalere, et al.
Pageof 5